We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
I Agree
Email registered. Please sign in.×
Enter your contact to build trust with supplier(s)×
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
From its inception in 2004, Shanghai Medicilon Inc. (STAR Market,
stock code: 688202.SH) has been committed to providing
comprehensive research and development (R&D) services to
biopharmaceutical companies, research institutions, and any
organizations working in the preclinical space, with the primary
objective of supporting and accelerating pharmaceutical,
biopharmaceutical and medical device R&D worldwide.
Main Competitive Advantages: International Approvals/Standards,Experienced R&D Staff,Contract Manufacturing (CRO,CMO),Quality Service
Other Competitive Advantages: AAALAC Animal facility;
GLP REGULATIONS;
Integrated service;
High qulity scientific staff;
Three party risk sharing;
Patents and Copyrights: When we co-operate with clients, all the results, data, and patents will belong to our clinets. We never asked been invlolved in.
Business Type: Agent,Distributor,Trading Company
R&D capacity:
Annual Turnover(USD):
Main Sales Markets: North America,Western Europe,Eastern Europe,Australasia,Asia
Other Competitive Advantages: AAALAC Animal facility;
GLP REGULATIONS;
Integrated service;
High qulity scientific staff;
Three party risk sharing;
Patents and Copyrights: When we co-operate with clients, all the results, data, and patents will belong to our clinets. We never asked been invlolved in.
Four years of qualification
Audited Supplier
Pharma Sources Insight JANUARY 2024
